Lung cancer, also known as lung carcinoma, is a malignant lung tumour characterized by uncontrolled cell growth in tissues of the lung. Lung cancer primarily occurs in people with high nicotine intake, or people who smoke. The risk of lung cancer increases with time and also with number of cigarettes smoked by an individual. There are no particular signs or symptoms for lung cancer at its initial stage. Lung cancer occurs only when the disease has advanced to a certain stage.
Increasing incidence of lung cancer across the globe, coupled with high awareness levels among the general population about cancer treatment, and continuous developments in surgery equipment are key factors driving growth of the global lung cancer surgery market. In addition, introduction of advanced healthcare infrastructure, increasing number of cigarette smokers, and less amount of time required for lung cancer surgeries using new advanced technologies are all major factors expected to fuel growth to the global lung cancer surgery market over the forecast period.
However, high cost of lung cancer surgery is a key factor restraining growth of the global lung cancer surgery market. Additionally, lack of skilled professionals for lung cancer treatment, and lack of appropriate infrastructure in developing economies are major factors expected to restrain growth of the global lung cancer surgery market over the forecast period.
The global lung cancer surgery market is segmented on the basis of device, procedure, and region. On the basis of region, into North America, Europe, Asia Pacific, Latin America, and Middle East and Africa.
Do Inquiry About Report Here: https://marketresearch.biz/report/lung-cancer-surgery-market/#inquiry
The market in North America accounted for highest revenue share in the global lung cancer surgery market, owing to presence of appropriate healthcare infrastructure, coupled with increasing incidence of lung cancer in the region. In addition, technological developments in surgical techniques is also expected to boost growth for the global lung cancer surgery market. The first robotic surgical system was used in Canada to treat early-stage lung cancer by removing the cancer, along with a lobe of the lung. The market in Asia Pacific is expected to expand with highest CAGR of X.X% over the forecast period. This can be attributed to increasing number of lung cancer patients, government initiatives in improving healthcare infrastructure, and high rate of cigarette consumption in the region.
Prominent players profiled in the global lung cancer surgery market report include Ethicon US, LLC., Accuray Incorporated, Teleflex Incorporated, KARL STORZ SE & Co. KG, Scanlan International, TROKAMED GmbH iI, NeoMend Inc., Olympus Corporation, Siemens Healthcare, and Richard Wolf GMBH.